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The developments in new approaches and
techniques in the animal cloning science led in
2004 to the establishment of the project Cloning
in Public. Two interrelated aims were assigned to
the project. One was to provide the EU
Commission and other interested parties with
recommendations on regulatory issues relating
specifically to the cloning of farm animal species.
The other was to stimulate public debate on the
subject. The present document is the project’s
final report. It sums up the recommendations
with regard to regulatory options.
It is the overall conclusion of the project that the
EU would be left with difficult processes of
decision-making if the cloning of farm animals
were to take place in agricultural production in
countries outside (likely) or within (at present
unlikely) the EU. Whether a decision is made to
rely on existing regulation or to introduce new,
specifically targeted legislation, concerns about
both free trade and social acceptability in Europe
will have to be negotiated.
Three main areas of application have been
identified. First, cloning techniques are already in
use in basic research, i.e. research aimed at the
acquisition of new knowledge about fundamental,
biological mechanisms. Second, cloning tech-
niques are also being used in biomedicine to
develop new medicines and treatments. Third,
cloning may in future be used for agricultural
purposes – that is, in the production of meat and
dairy products – with the aim of making
agricultural production more efficient. The first
two of these areas of application represent
developments that are either already taking place
or in the offing on a global scale. The third area of
application is controversial. It represents for the
time being a possible development that may take
place in some parts of the world but not in others
– a development, then, that may give rise to
international conflicts over trade. Specifically,
there are indications that cloning techniques may
be put to use in agricultural production in the USA
but not in the EU. This challenging eventuality
must be squarely faced by those considering the
regulatory options in the EU.
At present, there is no specific regulation on the
cloning of farm animal species in the EU. Thus, at
European level animal cloning is now governed
only by a rather complex, indirect regulatory
patchwork, incorporating general controls on, for
instance, the treatment of experimental animals in
research, the treatment of production animals in
agriculture, and the protection of human health
and the free choice of consumers. Much the same
is true in individual member states. Only one
country, Denmark, has added specific legislation
on animal cloning. When considering whether this
is a satisfactory state of regulatory affairs, possible
developments in the practical uses of cloning
must, of course, be taken into account. These
developments must be examined in the light of
wider issues of trade and social acceptability in the
EU.
One regulatory option would be to live with the
present EU regulation, possibly with a few
amendments. This may well suffice, given the
assumption that animals would only be cloned for
basic research and biomedical purposes. For
legislation on the uses of animals for such
purposes is already in place in the EU. Against this
background, the use of public resources to intro-
duce and implement new specific regulation could
be seen as wasteful. The caveat, however, would be
that the cloning of animals might give rise to
renewed public debate on the adequacy of the
existing regulation, and on whether, for instance,
that regulation provides sufficient protection for
animal integrity.
The EU will be presented with greater difficulties if
countries outside the EU – such as the USA, Japan,
Korea and Australia – decide to allow, and perhaps
even encourage, the introduction of animal
cloning within agricultural production and, thus,
the food chain. This is a likely development.
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1. SUMMARY
Even in this case, it can be argued that adequate
EU regulation is in place. Existing legislation to
protect consumers, human health and the
environment can be applied to imports of cloned
animals and products from such animals. This
legislation provides for risk assessments to be
carried out and acted upon, and evidence of risk is
the only legitimate basis on which to restrict
imports. This is a guiding principle of international
trade agreements. So far, however, no risks to
human health or the environment have been
shown to be associated with cloned animals and
their products. Thus, if the EU persists with the
existing regulation alone, and if cloning tech-
niques are applied for commercial agricultural
purposes in countries outside the EU, the import
of cloned animals and of products from such
animals is likely to go ahead. International
conflicts over free trade might be avoided. On the
other hand, internal conflicts within the EU might
develop, as they also might in the – at present
unlikely – event that the cloning of animals is
introduced into agricultural production within the
EU.
Groups of citizens, and even some member states,
would be likely to resist the import and/or
marketing (labelled or unlabelled) of cloned
animals and their products. This would prompt
discussion of the question whether ethical
concerns other than those relating to risk should
be given regulatory force. It is possible that such
ethical concerns would relate to utility, to the
protection of traditional agriculture and to the
integrity and naturalness of animals. Individual
member states might choose to regulate, as far as
possible, along such lines.
The other regulatory option is to introduce
specifically targeted EU legislation on the cloning
of farm animal species. This could make sense
given the combined assessment (i) that the cloning
in question will be used for commercial agri-
cultural purposes, and (ii) that – although this
might give rise to international trade disputes –
ethical concerns other than those relating to risk
should be taken into account to ensure that the
application of cloning techniques is socially
acceptable in a European context.
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The main aim of this report is to present the
recommendations of the project to the European
Commission and other interested parties. These
recommendations focus on three scenarios – or
possible developments – in which cloning is
applied differently. In connection with each
scenario key regulatory challenges are pointed out
and ethical concerns are identified.
The report draws on the six earlier reports of the
project (listed below) as well as on the pre-
sentations and deliberations of the four project
workshops and conferences (see below). The
earlier project reports can be referred to in the
course of more in-depth studies of particular
aspects of the cloning technology indicated in this
recommendation report. An earlier and quite
different version of this report was presented and
discussed at the final conference of the project in
October 2006. There, European citizens from
various backgrounds and countries – including
high school teachers, researchers working on the
project, other specialists on a range of aspects of
cloning, stakeholder representatives, and repre-
sentatives from the European Commission – as
well as a few specialists and stakeholder repre-
sentatives from the USA and Canada actively
participated.
The main objectives of Cloning in Public were: (a)
to develop recommendations on the preparation
of European regulation of, and guidelines
covering, research on farm animal cloning and its
possible applications; and (b) to stimulate in-
formed public debate across Europe on these
issues involving key stakeholders, university
students and members of the public.
It should be noted that in this report, as has been
the case throughout the project, the term “cloning”
refers to asexual reproduction – or, more precisely,
to the asexual reproduction of individuals with
genetic material that is virtually identical to that of
the “donor” animal supplying nuclear matter. In
recent debates, interest has centred on cloning by
somatic cell nuclear transfer (SCNT). The first
report from the project goes into the science and
technology of cloning in detail. The term “farm
animal” refers to farm animal species such as
ruminants (e.g. cows, sheep), pigs and poultry (e.g.
chicken, turkey). The term does not necessarily
imply that an animal is kept or used in an
agricultural setting or for agricultural purposes.
The potential application of a cloned farm animal
species may therefore be in the field of
biomedicine. The delimiting of the project to farm
animal species leads, on the other hand, to the fact
that neither triploid fish nor genetically modified
mice for use in research have been examined.
Cloning in Public reports:
1. Gjerris, Mickey & Gábor Vajta (2005). The
Science and Technology of Farm Animal
Cloning. A review of the state of the art of the
science, the technology, the problems and the
possibilities. Danish Centre for Bioethics and
Risk Assessment: Project Report 6. (This report
is also published in an amended version: Gábor
Vajta & Mickey Gjerris (2006). Review article:
Science and technology of farm animal
cloning: State of the art. Animal Reproduction
Science 92: 211-230).
2. Meyer, Gitte (2005). Why clone farm animals?
Goals, motives, assumptions, values and con-
cerns among European scientists working with
cloning of farm animals. Danish Centre for
Bioethics and Risk Assessment: Project Report 8.
3. Lassen, Jesper (2005). Public perceptions of
farm animal cloning in Europe. Danish Centre
for Bioethics and Risk Assessment: Project
Report 9.
4. Gamborg, Christian; Jennifer Gunning & Mette
Hartlev (2005). Farm Animal Cloning: The
Current Legislative Framework. A review
describing the existing law, and its practical
application within and beyond the EU. Danish
Centre for Bioethics and Risk Assessment:
Project Report 12.
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2. THE REPORT AND THE PROJECT
5. Gunning, Jennifer; Mette Hartlev & Christian
Gamborg (2006). Challenges in regulating farm
animal cloning: an assessment of regulatory
approaches and the legal framework within the
EU. Danish Centre for Bioethics and Risk
Assessment: Project Report 13.
6. Gjerris, Mickey (2006). Ethics and farm animal
cloning. Risks, values and conflicts. Danish
Centre for Bioethics and Risk Assessment
Project Report 14.
7. Gamborg, Christian; Mickey Gjerris; Jennifer
Gunning; Mette Hartlev: Gitte Meyer; Peter
Sandøe & Geir Tveit (2006). Regulating farm
animal cloning. Recommendations from the
project Cloning in Public. Danish Centre for
Bioethics and Risk Assessment: Project Report
15. 
Cloning in Public workshops:
1. Seville 9-10 June 2005 (co-organised with EC
Joint Research Centre IPTS) – an expert and
stakeholder workshop designed to explore the
current science, or state of the art, in cloning
and possible applications of cloning tech-
nology to farm animal species.
2. Prague 24-25 November 2005 – an expert and
stakeholder workshop designed to explore the
ethical and regulatory aspects of research on,
and uses of, cloning of farm animal species.
3. Copenhagen 23-24 September 2006 – a citizen’s
workshop intended to familiarise a number of
European high school teachers with the key
issues raised by the cloning of farm animal
species in order for them to take active part in
the final project conference in Brussels.
4. Brussels 5-6 October 2006 – a “participatory
conference” bringing specialists, stakeholders,
politicians and non-specialist citizens together
to deliberate on the issues raised by the cloning
of farm animal species in order to further
improve the project’s final recommendations
to the European Commission.
Project reports, together with summaries of the
workshops, can be found at the project website:
http://www.sl.life.ku.dk/cloninginpublic.htm
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At EU level, animal cloning is presently governed
by an indirect regulatory framework. That is, to
date, the EU has passed no binding legal
instruments specifically controlling animal
cloning. Moving to the national level, only one of
the twenty-five member states has specific
legislation on the cloning of farm animals.
One of the main discussion points of the project
workshop in Prague, in November 2005, was
whether farm animal cloning, in plausible
developmental scenarios, would be adequately
regulated by present EU legislation; and if not, how
it might otherwise be regulated. The question was
raised again at the final project conference in
Brussels, in October 2006. Here two sub-questions
were identified: (1) At what level and how should
the technology be regulated? (2) Upon what
considerations should any regulation be based?
3.1 Possible developments and 
regulatory options
To ensure that the discussion is thorough, realistic
and sound, a range of possible developments in
the applications of cloning and several ensuing
regulatory options are explored in this report.
Within these scenarios, potential applications of
the technology outside Europe (and in particular
in the USA) are included so that trade issues are
addressed.
The potential areas of application that have
emerged during the project workshops and
through interviews with farm animal cloning
scientists can be divided in three main categories:1
• Basic research. Basic research aimed at under-
standing embryonic development or gaining
knowledge about epigenetic processes, or
laying the base on which to develop disease
models.
• Biomedicine. Reproductive cloning as a tool for
efficient production of transgenic animals that
will serve mostly as disease models improving
the understanding of human diseases. Such
animals can also be used in the production of
pharmaceuticals or, possibly, as organ donors.
• Agriculture. Reproductive cloning propagating
a desirable genotype which could be used to
reduplicate individual animals2 with high
genetic merit.3
The main regulatory options identified throughout
the project are4:
• Using existing EU regulation. One possibility is
to regulate farm animal cloning through
existing regulatory mechanisms at EU level –
potentially, with a few small adjustments. 
• New EU regulation. An alternative is to intro-
duce new regulation at EU level specifically to
cover farm animal cloning.
• National regulation. It must be taken into
account that individual member states may
introduce their own national regulation inde-
pendently, i.e. even if no specific regulation at
EU level is introduced.
Below, three contrasting, possible combinations of
the application of farm animal cloning in and
outside the EU are considered in relation to the
three regulatory approaches (Figure 1).
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3. APPLICATIONS AND REGULATION
1 These categories should not be assumed to be distinct and independent of one another.
2 The prospect of mass production of animals with particularly valuable treats has been mentioned.
3 Reproductive cloning could also be used on a small scale to produce specimens of endangered species, pets or sports
animals.
4 The three options are not mutually exclusive; different combinations of them can be imagined.
Figure 1. The relationship between three
contrasting, possible combinations of the
application of farm animal cloning and the three
main regulatory options can be illustrated by a 
matrix. This report seeks to fill in the empty spaces 
of the matrix.
1. In the first application combination, farm
animal cloning is taken, within the EU and
globally, to be used primarily for basic research
purposes (e.g. to deepen understanding of
basic reproduction or cell formation processes)
and/or biomedical aims (the production of
animals used as disease models or bioreactors).
Agricultural applications – mainly in breeding
and reproduction for traditional farming
purposes – and other uses, such as the
production of companion animals or the
protection of endangered species, are assumed
to be marginal.
2. In the second combination, applications in
Europe are taken to be predominantly in basic
research and biomedicine, but in addition
globally (e.g. the USA, Korea, Japan, Australia),
agricultural applications are assumed to play
an important role.
3. It is in the third combination that the most
extensive developments are envisaged. Here,
agricultural applications of farm animal
cloning are envisaged to be used on a large
commercial scale within the EU (as well as
elsewhere) along with basic research and
biomedical research.
In two of the three combinations, the uses of farm
animal cloning are taken to be similar within the
EU and elsewhere. Apart from labelling issues,
there are no specific questions relating to trade.
When it is assumed, however, that agricultural
applications are used only outside the EU, trade-
related questions become important. For example,
a European ban on imports might lead to trade
sanctions.
The project has identified three realistic, regulatory
options that could be used to regulate the
technology, each of which can be considered in
connection with all three application combinations. 
1. The first is to regulate farm animal cloning
through existing mechanisms at EU level,
potentially with some small adjustments. 
2. The second is to introduce new regulation at
EU level specifically to deal with farm animal
cloning. 
3. In the third option, individual member states
are taken to introduce their own cloning
regulation (i.e. national regulatory instruments
that do not implement EU regulations or
directives).
It should not be assumed that these three
regulatory options are exclusive and exhaustive.
Clearly, they could be combined in various ways.
However, if for the sake of argument we treat the
options as separate ones, they and the three
application combinations yield nine future
scenarios.
In what follows, most of these scenarios will be
discussed. For each application combination, it
can be discussed whether existing legislation is
adequate or whether new regulatory mechanisms
would be required. It can be asked what un-
certainties there may be, and which steps may
need to be taken. When it comes to new regulation,
whether at national or EU level, many legal models
and tools can be employed. Here the advantages
and costs of new statutory law, administrative
rules or guidelines must be analysed.
3.2. Regulatory options
In trying to come to a decision about which of the
regulatory options to pursue, it is necessary to
have a clear understanding of what the regulation
is intended to achieve. Several factors may play a
role in any decision about how to regulate. 
In principle regulation could target either specific,
intended applications of the technology or the
12
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technology as such, but in practice it is difficult to
pinpoint the boundaries between the two. It is
often unclear what a technology might, in future,
be used for at the time it is developed. This
unclarity readily arises when a technique is
developed in order to gain knowledge about basic
biology and subsequently shows its usefulness
outside the laboratory of basic research. However,
it can also arise when research has a defined
technological purpose. Even when a technological
purpose is pre-defined, successful development of
the technology often leads to an array of other uses
which were not, and could not, be foreseen. Often,
however, the intended development of a
technology is unsuccessful. So, regulating a
technology as such at an early stage of its
development may lead either to restrictions on
unforeseen but desirable uses of the technology, or
to unnecessary legislative activity vis-à-vis a
technology that will never be of any importance. If,
on the other hand, the regulation targets specific
intended purposes, again there will be a
considerable risk of placing controls on something
that will never become a practical possibility, while
other unforeseen uses are left unregulated.
A number of values and concerns are at play in
these decisions, including consumer protection,
citizen rights, consumer choice, economic de-
velopment, innovation, product safety, public
health, animal welfare and animal integrity. No
interpretation and assessment of the relative
importance of these concerns can take place in a
vacuum. Public debate will and should play an
important role. As it is, public debate about
biotechnology in Europe has been characterised
by a divide between, on the one hand, biomedical
applications of biotechnology and, on the other
hand, applications relating to agriculture and food
production. The former command a certain
degree of acceptance whereas the latter are widely
rejected. This may of course change in the light of
further public debate. At the time being, the divide
in public perception of biotechnology will
probably affect the way in which the different
concerns are interpreted, and the weight they are
given in assessments of applications of farm
animal cloning.  
Regulatory bodies use various forms of regulation,
depending on their status and powers. A statutory
administrative body, such as an environmental
protection agency, can create “administrative
regulations” that are legally binding standards. The
issuing of guidelines, recommendations or
documents describing best practice is also
possible. Such guidelines, of course, provide just
that – guidance. As such they are not legally
binding, although in practice they are often viewed
as binding because they are issued by a public
authority. A special licensing system can also be
put into place. An example would be a system in
which it is necessary to obtain a licence to clone
specific animals. Systems of this kind designed to
regulate animal experimentation operate in many
countries. Another example is a licence allowing
specific companies and research institutions to
clone animals.
Where existing regulation is considered in-
sufficient, policy makers will need to take a
statutory approach. When doing so, they should
consider not only the aims of future regulation but
also any implications such legislation might have
so far as enforcement and economic impact are
concerned. In a statutory approach a range of
regulatory options are available, applying to any of
the scenarios:
1. The most restrictive option is to enact
prohibitionary legislation with penalties for
failure to comply.
2. Another option is to enact detailed legislation
taking account of all aspects of the technology,
prohibiting certain activities and allowing
others. This may give rise to hard questions
about how to apply the legislation in an area
where the forefront of science rapidly changes.
3. A third option is to enact framework legislation
which is mainly permissive (although some
activities may still be prohibited with penalties
for infringement), but with regulation carried
out through licensing activities by a regulatory
body. 
In the following, the different combinations of
applications and possible regulatory approach are
considered in greater detail5.
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5 The content under each possible development should be seen as progressive, so that (to give an example) regulatory
aspects of biomedical applications will only be stated under the first development. The report was prepared in this way in
an effort to avoid needless repetition.
3.3. Possible development 1: Basic research and
biomedicine applications in and outside the EU
Discussions at all the project workshops have
clearly demonstrated an absence of consensus
among scientists as to what applications are
technically possible, economically sound and
ethically acceptable. However, within biomedicine
commercial applications have already emerged. In
the EU several “pharming” applications are at the
last stage of clinical trials and one has been
approved by the EU for commercial use. Whether
these applications will, in the long run, be
economically feasible is still an open question. In
relation to such biomedical applications, reliance
could be placed on existing legislation (with some
small amendments), together with existing
procedures and guidelines governing the approval
of pharmaceutical/medicinal products.
According to the Opinion of the Group of Advisers
on Ethical Implications of Biotechnology6 to the
European Commission – a document that has no
legally binding status – the cloning of farm animal
species for research is acceptable only if it is
carried out under conditions which avoid or
minimise animal suffering.7 The group supported
animal cloning research on the basis that such
research was likely to add to the knowledge and
understanding of biological processes.
Across Europe, in EU member states, there is a raft
of legislation implementing the European
Directive 86/609/EEC on the protection of animals
used for experimental and other scientific pur-
poses. Within the EU, any uses of farm animal
cloning in basic research and biomedical research
would have to comply with this legislation.
Experimental animal use is, according to this
legislation, acceptable, provided that alternative
means of achieving the same result are duly
considered, care is taken to keep the animals
under good conditions, and great effort is put into
designing experiments so that results can be
achieved with no or minimal suffering by the
animals. Typically, for each experiment a
committee will have to assess whether these
conditions are fulfilled. An impact assessment of a
revision of the Directive is currently (2006) on-
going. Moreover, there is specific legislation on
animal experimentation in the individual
countries.
The member states of the Council of Europe have
agreed on a convention, with legally binding
status, including a number of appendices on
specific animal species.8 The European Con-
vention’s provisions cover areas such as care and
accommodation, the conduct of experiments,
humane killing, authorisation procedures, control
of breeding or supplying and user establishments,
education and training, and statistical infor-
mation.
If farm animal cloning comes, both globally and
within the EU, to be used primarily for basic
research purposes (e.g. to deepen understanding
of basic reproduction or cell formation processes)
and/or biomedical purposes (the production of
farm animals to be used as disease models or
bioreactors), existing legislation would cater for an
array of ethical concerns. Thus, concerns centred
on risks to humans and the environment, and on
the obvious welfare problems produced by
research, could be taken into account. Other
ethical concerns, however, such as those relating
to the integrity or naturalness of animals, could
not be taken into account.
3.4 Possible development 2: Basic research and
biomedicine applications in and outside the EU,
and agricultural applications outside the EU
It is possible that, within the EU, animal cloning
techniques would be used exclusively for basic
research and biomedical purposes, whereas in
countries outside the EU (e.g. the USA, Korea,
Japan, Australia and Canada) their employment
would be extended to include commercial
agricultural uses.
At the final project conference in Brussels high-
ranking representatives of European farm animal
breeder organisations reaffirmed that they do not
14
6 The group was succeeded in December 1997 by the “European Group on Ethics in Science and New Technologies” (EGE).
7 Opinion of the Group of Advisers on the Ethical Implications of Biotechnology to the European Commission. Ethical aspects
of cloning techniques, 28 May 1997.
8 European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes (ETS No.
123), and Protocol of Amendment to the European Convention for the Protection of Vertebrate Animals used for Experimental
and other Scientific Purposes (ETS No. 170).
see any use, in the foreseeable future, for farm
animal cloning in breeding and reproduction. This
is in line with the official policy of the umbrella
body European Forum of Farm Animal Breeders
(EFFAB). However, a more favourable evaluation of
the future awaiting agricultural applications has
been reached in the USA.
The competent authority in the USA, the Food and
Drug Administration (FDA), is in the process of
developing regulatory policies on meat and milk
from cloned animals and their offspring. At the
end of December 2006 a draft risk assessment, a
proposed risk management plan, and a draft
guidance for industry were issued. The main
conclusions were that meat and milk from clones
of adult cattle, pigs and goats, and their offspring,
are as safe to eat as food from conventionally bred
animals.(http://www.fda.gov/bbs/topics/NEWS/
2006/NEW01541.html).
In Canada regulation on animal biotechnology
exists, but not a regulatory approach to cloned
animals. An interim policy on foods derived from
cloned animals is in use. Australia is developing a
government position on the sale of non-
genetically modified cloned animals as food. New
Zealand does not have any particular regulation
regarding animal cloning. Nor does Japan. It has
been reported that Japan is now close to approving
beef and milk from cloned cows and their
offspring for human consumption on the basis of
risk assessment studies that reportedly show these
products to pose no risks to human health. Other
countries may, as a result of public consultation,
seek either to prohibit animal cloning or restrict it
to certain applications.
Denmark is the only EU member state with
legislation restricting animal cloning to research
and biomedical purposes. However, so far Danish
law has remained silent on the importation of
cloned animals or products from such animals.
The Danish act’s principal aim is to protect the
welfare and integrity of animals while at the same
time permitting research that could have
substantial benefits for human health. Norwegian
law also restricts animal cloning to research
purposes. In Norway, who is not an EU member,
the principal aim of cloning law is to prevent
human cloning, and the law is again silent on the
importation of cloned animals and products from
such animals. The potential issues raised by trade,
and in particular imports, if the regulation of
cloning were to be secured through specifically
introduced member state legislation were
identified as one of the most difficult challenges at
the final project conference in Brussels.
World Trade Organisation (WTO) agreements
apply at both the national and the European level.
Hence individual countries will probably be
reluctant to enact legislation that is likely to be
challenged in international courts, such as the
International Court of Justice. Within both the EU
and the European Economic Area (EEA) internal
market provisions require the freedom of
movement of goods, although within the EEA
agriculture and fisheries are covered by WTO
agreements only to a very limited extent. In
principle, however, member states are not
permitted to restrict imports of products derived
from cloned animals or their offspring from fellow
member states unless a risk can be scientifically
demonstrated, as happened with meat products
from the UK during the Bovine Spongiform
Encephalopathy (BSE) outbreak.
Consequently, WTO agreements and EU legis-
lation could conflict with national efforts to place
restrictions on imports and exports of cloned
animals. The question of cloning imports was
discussed in the Danish Parliament when the act
on animal cloning was debated. The government
promised that administrative rules would be
created restricting imports to cloned animals
intended for use in research and requiring prior
authorisation. However, so far no such rules have
been introduced, and thus importation, to
Denmark, of cloned animals and products from
such animals is not restricted.9
So far as patenting is concerned, there are
unresolved legal issues at both the international
and EU level about the ownership and
patentability of the basic process of producing
cloned animals through SCNT, the patentability of
the animals created thereby, and the patentability
of derived products. These issues have been
considered by courts, such as the European Court
15
9 In November 2006 the Danish Government took its first steps in the process of introducing import restrictions into Danish
law.
of Justice, and the European Patent Office. They
deserve greater public discussion. The EU
Directive 98/44/EC on the legal protection of
biotechnological inventions, while stating that
human cloning cannot be the subject matter of a
patent, is silent on animal cloning. This may seem
to suggest that animal cloning is thought to be
considered suitable for patenting. However, since
the listing in the directive of non-patentable
procedures and products is not intended to be
exhaustive, it remains possible that the patenting
of a cloned animal will be deemed contrary to
ordre public and morality. In addition, the
question remains whether the invention
requirement governing patents is fulfilled when it
comes to cloned animals.
The most pressing question within this scenario is
whether a country or a region will be able either to
restrict imports of cloned animals or products
derived from them or their progeny, or insist on a
certain kind of labelling, if the arguments are
based on ethical concerns other than risks to
human health or the environment. A conflict
rather similar to that over genetically modified
crops in the 1990s – where industry lobbied
strongly against various legislative reforms, being
particularly unhappy about labelling regardless of
detectability –  may well arise again.
3.5 Possible development 3: Basic research,
biomedicine and agricultural applications in 
and outside the EU
Although animal cloning for general agricultural
purposes does not seem likely, now or in the near
future, within the EU, this development should be
considered, as it may have implications for the
questions whether, and if so how, to regulate.
Existing regulation
If existing regulation were relied upon, no direct
action would be taken to control animal cloning as
such. We would have to rely on control
mechanisms already in place, and indirect
regulation would be allowed to evolve by way of
amendments to existing legislation (e.g. laws
requiring the labelling of meat from cloned
animals) and through professional codes of
practice, international trade agreements and
patent law, together with public pressure and
market forces. This is very much the situation in
the USA, where federal legislation cannot be used
to prohibit an activity such as animal cloning
unless it can be shown that there is a risk to human
health.
Unlike the genetic modification of animals, animal
cloning is not directly regulated at EU level.
However, a body of binding EU legislation, in the
form of regulations and directives, addresses
issues such as food safety and animal health and
welfare. Additionally, zootechnical legislation
regulating the trade of breeding animals might be
of relevance to cloned animals used for breeding
purposes, and animal identification legislation
regulates the tracking of farm animals. There is
also a collection of measures addressing
genetically modified organisms, and these
measures will apply to cloned genetically modified
animals. Consumer protection is largely addressed
through novel foods and labelling regulations.
Nevertheless, some uncertainty and possible gaps
remain in relation to farm animal cloning.
Essentially, the risk aspect of animal cloning
breaks down into lower-level questions about
animal health and welfare, human health,
environmental effects and food safety. So far very
few studies of the risks of farm animal cloning
have been published. With regard to product safety
issues, existing EU measures already require
member states to take a number of actions to
guarantee food safety and consumer choice. EU
food law does not specifically address products
from cloned animals or their offspring, but it
includes the mechanisms to do so. 
From a “consumer rights” perspective, it could be
argued that there is a legal void if food products
from cloned animals or their progeny are covered
neither by the regulation of novel foods nor the
regulation of genetically modified food.
New legislation at EU level
Under the treaty establishing the European
Community, the European Commission has the
“right of initiative”. This means that the Com-
mission is responsible for drawing up new
legislative proposals to put before the European
Parliament and Council. On the other hand, the
Commission will in general take action at EU level
only if it believes that a problem cannot be
addressed more effectively by national, regional or
local action (the principle of subsidiarity).
The European Commission can seek to regulate by
introducing binding legal instruments (regu-
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lations, directives and decisions) or non-binding
instruments (recommendations and opinions). In
practice consensus on new EU controls on animal
cloning could be difficult to achieve, as became
evident at the final project conference in October
2006. Public opinion on the issue is less than clear-
cut, particularly since, potentially, the technology
has applications ranging from livestock improve-
ment, providing animal models for medical
research, “pharming” and the production of
specialised foods such as humanised cow’s milk
for infants.
National regulation in EU member states
To date only two European countries have enacted
legislation on animal cloning: Denmark, an EU
member state, and Norway, a member of the EEA.
In other European countries the regulation of
animal cloning is therefore indirect and relies on
existing laws, operating at the national level, on
animal protection and animal biotechnology.
Institutional research ethics committees also play
a non-statutory role.
3.6 Assessing regulatory options
In assessing regulatory approaches it is necessary
to address the challenges that may arise from
changes to the current regulatory framework.
These include identifying the aims of further
regulation (e.g. ensuring food safety) and then
designing appropriate regulatory responses. The
responses here will involve finding a suitable level
of regulation (e.g. the level of EU directives),
deciding upon a regulatory model (such as a rule
model), and finally, determining the appropriate
regulatory tool (such as binding administrative
rules). 
In planning regulatory apparatus for the control of
farm animal cloning within the EU it is paramount
to develop a common understanding of what the
regulation is intended to achieve and what its
underlying values are. No matter how the EU
chooses to act, it will be necessary to explain the
values underlying the choice.
However, it is also important, as has been argued
in this report, to have a realistic view of the ways in
which the technology of farm animal cloning is
likely to be applied. The main uncertainty here is
whether the technology will, on any considerable
scale, be used within the production of meat and
other animal consumables – or whether, instead, it
will only be used for basic research and biomedical
purposes. Given the divide in public perceptions,
in Europe at any rate, of biomedical applications of
biotechnology and applications relating to
agriculture and food production, it may make a
significant difference which scenario turns out to
be closest to actual events.
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